Abstract
Obesity is a major health problem and as a result, it is reasonable to consider pharmacological approaches alongside approaches involving diet, physical activity and lifestyle change. The currently available drugs, sibutramine and orlistat, result in modest, clinically worthwhile weight loss, with demonstrable improvements in co-morbidity, but do not meet the often unrealistic expectations of patients or health care professionals managing obese patients. There is insufficient data on efficacy or safety of other agents to support their use. Many new pharmacological approaches are under investigation. These include gut hormones, such a peptide YY (3-36) and cholecystokinin that normally signal satiety, and centrally acting agents such a serotonin agonists, the anticonvulsants topiramate and zonisamide, cannabinoid receptor antagonists and drugs that act on other peptide neurotransmitter systems such as NPY and the melanocortins. Given the multiple pathways that influence energy balance, it is likely that therapies targeting more than one control system may be required in the future to meet the expectations and needs of patients needing to lose weight for medical reasons.
Keywords: anti-obesity drugs, obesity, sibutramine, anticonvulsants topiramate, cannabinoid receptor antagonists
Current Drug Targets
Title: Clinical Evaluation of Anti-Obesity Drugs
Volume: 5 Issue: 3
Author(s): John Wilding
Affiliation:
Keywords: anti-obesity drugs, obesity, sibutramine, anticonvulsants topiramate, cannabinoid receptor antagonists
Abstract: Obesity is a major health problem and as a result, it is reasonable to consider pharmacological approaches alongside approaches involving diet, physical activity and lifestyle change. The currently available drugs, sibutramine and orlistat, result in modest, clinically worthwhile weight loss, with demonstrable improvements in co-morbidity, but do not meet the often unrealistic expectations of patients or health care professionals managing obese patients. There is insufficient data on efficacy or safety of other agents to support their use. Many new pharmacological approaches are under investigation. These include gut hormones, such a peptide YY (3-36) and cholecystokinin that normally signal satiety, and centrally acting agents such a serotonin agonists, the anticonvulsants topiramate and zonisamide, cannabinoid receptor antagonists and drugs that act on other peptide neurotransmitter systems such as NPY and the melanocortins. Given the multiple pathways that influence energy balance, it is likely that therapies targeting more than one control system may be required in the future to meet the expectations and needs of patients needing to lose weight for medical reasons.
Export Options
About this article
Cite this article as:
Wilding John, Clinical Evaluation of Anti-Obesity Drugs, Current Drug Targets 2004; 5 (3) . https://dx.doi.org/10.2174/1389450043490479
DOI https://dx.doi.org/10.2174/1389450043490479 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Markers of Early Vascular Ageing
Current Pharmaceutical Design Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Meet Our Editorial Board Member
Current Traditional Medicine Transplantation of Adipose Tissue-Derived Stem Cells for Treatment of Focal Cerebral Ischemia
Current Neurovascular Research Engineered Probiotic and Prebiotic Nutraceutical Supplementations in Combating Non-communicable Disorders: A Review
Current Pharmaceutical Biotechnology Rapid and Simple Profiling of Lipoproteins by Polyacrylamide-Gel Disc Electrophoresis to Determine the Heterogeneity of Low-Density Lipoproteins (LDLs) Including Small, Dense LDL
Recent Patents on Cardiovascular Drug Discovery Editorial: [Hot Topic: Establishment of the Australian Infectious Diseases Research Centre]
Current Drug Targets Magnesium and Anaesthesia
Current Drug Targets Cardiovascular Disease: A Target for the Pharmacological Effects of Quercetin
Current Topics in Medicinal Chemistry Chronic Heart Failure- Potential for Pharmacological Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Phenolic Compounds as Antioxidants: Carbonic Anhydrase Isoenzymes Inhibitors
Mini-Reviews in Medicinal Chemistry Perspectives on Medicinal Properties of Mangiferin
Mini-Reviews in Medicinal Chemistry Patients with Rheumatic Diseases Overlooked during COVID-19 Pandemic: How are They Doing and Behaving?
Current Rheumatology Reviews Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry Mean Platelet Volume During Ischemic Stroke is a Potential Pro-inflammatory Biomarker in the Acute Phase and During Neurorehabilitation Not Directly Linked to Clinical Outcome
Current Neurovascular Research Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Scorpion Extracts Inhibit Tumor Growth in Esophageal Cancer and Lung Adenocarcinoma
Current Signal Transduction Therapy Cardiovascular Effects of Current and Future Anti-Obesity Drugs
Current Vascular Pharmacology Miracles of Herbal Phytomedicines in Treatment of Skin Disorders: Natural Healthcare Perspective
Infectious Disorders - Drug Targets Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA